<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>JHS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">JHS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="jhs-svendgaard-laboratories-limited" class="section level1">
<h1>JHS Svendgaard Laboratories Limited</h1>
<p><a href="/reports01/index/industry/rp-PersonalCare.html">Personal Care</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.JHS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on a thorough analysis of the provided financial reports, disclosures, and corporate communications for <strong>JHS Svendgaard Laboratories Limited</strong> (CIN: L74110HP2004PLC027558; NSE: JHS), here is a comprehensive assessment of the company‚Äôs <strong>headwinds, tailwinds, growth prospects, and key risks</strong>.</p>
<hr />
<div id="executive-summary" class="section level9">
<p class="heading">üìå <strong>Executive Summary</strong></p>
<p>JHS Svendgaard is a niche Indian pharmaceutical company with a primary focus on <strong>oral care products</strong>. The firm recently raised significant capital via <strong>preferential allotment and convertible warrants</strong> and is undergoing a strategic transformation in fund utilization, including entering new markets (e.g., Jammu &amp; Kashmir) and injecting capital into group entities. While profitability in the first half of FY26 has improved year-on-year, the company faces volatility in working capital management and negative cash flows from operations, raising liquidity and sustainability concerns.</p>
<hr />
</div>
<div id="tailwinds-positive-factors" class="section level6">
<h6>üî∫ <strong>Tailwinds (Positive Factors)</strong></h6>
<div id="strong-revenue-growth" class="section level9">
<p class="heading">1. <strong>Strong Revenue Growth</strong></p>
<ul>
<li><strong>Standalone Revenue (Q1 FY26)</strong>: ‚Çπ2345.41 crores (vs.¬†‚Çπ2054.16 crores in Q1 FY25) ‚Äî <strong>~14.2% YoY growth</strong>.</li>
<li>Indicates resilience in core oral care and OTC pharmaceutical segments, even in a competitive environment.</li>
<li>Diversification into non-oral care segments or private label opportunities may be contributing.</li>
</ul>
</div>
<div id="improved-profitability" class="section level9">
<p class="heading">2. <strong>Improved Profitability</strong></p>
<ul>
<li><strong>Net Profit (Q1 FY26)</strong>: ‚Çπ105.57 crores (vs.¬†<strong>‚Çπ0.62 crores net loss</strong> in Q1 FY25).</li>
<li>Turnaround from loss to profit reflects better cost control, one-time tax benefits, or improved gross margins.</li>
<li><strong>Positive deferred tax impact</strong> of ‚Çπ42.75 crores contributed significantly ‚Äî could reflect reversal of earlier provisions.</li>
</ul>
</div>
<div id="capital-infusion-strategic-repurposing-of-funds" class="section level9">
<p class="heading">3. <strong>Capital Infusion &amp; Strategic Repurposing of Funds</strong></p>
<ul>
<li>Raised ‚Çπ3000 crores through preferential share &amp; warrant issue (‚Çπ2000 + ‚Çπ1000) in August 2024.</li>
<li>Shareholders approved <strong>fund re-allocation</strong> in June 2025:
<ul>
<li>‚Çπ1650 crores diverted from general corporate use to <strong>infusion into subsidiary JHS Svendgaard Retail Ventures Ltd.</strong> for expansion.</li>
<li>Indicates confidence in scaling up a retail-focused or specialty pharma arm.</li>
</ul></li>
<li>Funds not immediately used are parked in fixed deposits (‚Çπ1200+ crores), preserving capital.</li>
</ul>
</div>
<div id="minimal-exceptional-items" class="section level9">
<p class="heading">4. <strong>Minimal Exceptional Items</strong></p>
<ul>
<li>No major write-offs or one-time losses ‚Äî cleaner P&amp;L.</li>
<li>Supports operational consistency and management‚Äôs credibility in forecasting.</li>
</ul>
</div>
<div id="market-confidence-earnings-per-share" class="section level9">
<p class="heading">5. <strong>Market Confidence (Earnings Per Share)</strong></p>
<ul>
<li><strong>EPS (Basic &amp; Diluted) of ‚Çπ0.12</strong> (Q1 FY26 vs.¬†<strong>loss of ‚Çπ0.02</strong> in Q1 FY25).</li>
<li>Positive trend signals improving value per share.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges-negative-trends" class="section level6">
<h6>üîª <strong>Headwinds (Challenges &amp; Negative Trends)</strong></h6>
<div id="negative-operating-cash-flow" class="section level9">
<p class="heading">1. <strong>Negative Operating Cash Flow</strong></p>
<ul>
<li><strong>Operating Cash Flow (6 months ended Sep‚Äô25)</strong>: <strong>‚Äì‚Çπ293.33 crores</strong>.</li>
<li>Despite reported profits, cash is being drained by:
<ul>
<li>Sharp <strong>increase in receivables</strong> (+‚Çπ142 crores, though still down YTD).</li>
<li><strong>Working capital buildup</strong> across multiple lines (inventory, other current assets).</li>
</ul></li>
<li>This signals potential strain on liquidity and reliance on financing.</li>
</ul>
</div>
<div id="liquidity-concerns" class="section level9">
<p class="heading">2. <strong>Liquidity Concerns</strong></p>
<ul>
<li>While the company has <strong>‚Çπ1,681.90 crores in cash &amp; equivalents</strong> (Sep‚Äô25), this is heavily reliant on recent equity funding.</li>
<li>Cash balances rose from ‚Çπ672.18 crores (Mar‚Äô25) to ‚Çπ1,681.90 crores ‚Äî largely due to capital raise.</li>
<li>If operating cash outflows continue, cash reserves could erode.</li>
</ul>
</div>
<div id="high-other-current-assets" class="section level9">
<p class="heading">3. <strong>High ‚ÄúOther Current Assets‚Äù</strong></p>
<ul>
<li><strong>‚ÄúOther Current Assets‚Äù</strong> spiked from ‚Çπ871 crores (Mar‚Äô25) to <strong>‚Çπ1,347 crores</strong> (Sep‚Äô25) ‚Äî increase of <strong>‚Çπ476 crores</strong>.</li>
<li>Possible reasons: advances to suppliers, inter-company loans, unaccounted receivables, or tax assets.</li>
<li>Requires deeper scrutiny ‚Äî could be a red flag if non-recoverable.</li>
</ul>
</div>
<div id="project-delays-capital-expenditure" class="section level9">
<p class="heading">4. <strong>Project Delays &amp; Capital Expenditure</strong></p>
<ul>
<li><strong>Capital Work in Progress (CWIP)</strong> increased by ‚Çπ294.50 crores (Sep‚Äô25 vs.¬†Mar‚Äô25), indicating ongoing large-scale investments.</li>
<li>These are likely linked to J&amp;K project ‚Äî <strong>only ‚Çπ71.29 crores utilized so far</strong> against allocated ‚Çπ599.99 crores.</li>
<li>Raises concerns about execution pace and ROI timelines.</li>
</ul>
</div>
<div id="inventory-buildup" class="section level9">
<p class="heading">5. <strong>Inventory Buildup</strong></p>
<ul>
<li>Inventory rose from ‚Çπ1188.34 crores to ‚Çπ1387 crores in Q2 FY26 ‚Äî <strong>+‚Çπ198.65 crores</strong>.</li>
<li>This, combined with receivables growth, increases <strong>working capital cycle pressure</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6>üöÄ <strong>Growth Prospects</strong></h6>
<div id="expansion-via-subsidiary-retail-venture" class="section level9">
<p class="heading">1. <strong>Expansion via Subsidiary (Retail Venture)</strong></p>
<ul>
<li><strong>‚Çπ1650 crores to be infused</strong> into <strong>JHS Svendgaard Retail Ventures Ltd.</strong> ‚Äî suggests a strategic push into <strong>branded retail, specialty pharma, or consumer healthcare retailing</strong>.</li>
<li>Could open new revenue streams beyond manufacturing.</li>
</ul>
</div>
<div id="greenfield-project-in-jk" class="section level9">
<p class="heading">2. <strong>Greenfield Project in J&amp;K</strong></p>
<ul>
<li>Under Industrial Development Scheme (IDS) 2021‚Äì2030 ‚Äî offers <strong>tax incentives and infrastructure support</strong>.</li>
<li>Located in a special economic zone ‚Äî potential for <strong>long-term margin benefits</strong>.</li>
<li>Expected to diversify production base and access incentives.</li>
</ul>
</div>
<div id="strong-cash-reserves-post-fund-raise" class="section level9">
<p class="heading">3. <strong>Strong Cash Reserves Post Fund raise</strong></p>
<ul>
<li>With <strong>‚Çπ3000 crores raised</strong> and <strong>‚Çπ1200 crores parked</strong>, company has flexibility to fund future growth, M&amp;A, or market expansion.</li>
</ul>
</div>
<div id="single-segment-focus-oral-care" class="section level9">
<p class="heading">4. <strong>Single Segment Focus (Oral Care)</strong></p>
<ul>
<li>Clear operational focus ‚Äî can leverage brand, R&amp;D, and distribution in a <strong>high-margin niche market</strong>.</li>
<li>India‚Äôs oral healthcare market is growing (~<strong>8‚Äì10% CAGR</strong>) ‚Äî JHS is well-positioned as a key domestic player.</li>
</ul>
<hr />
</div>
</div>
<div id="key-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="57%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk</th>
<th>Analysis</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>1. Liquidity &amp; Working Capital Risk</strong></td>
<td>Negative operating cash flow despite profit suggests <strong>earnings are not converting into cash</strong>. Dependency on equity funding is unhealthy long-term.</td>
</tr>
<tr class="even">
<td><strong>2. Execution Risk in New Projects</strong></td>
<td>Delayed capex deployment in J&amp;K project highlights possible <strong>project management, bureaucratic, or infrastructural hurdles</strong>.</td>
</tr>
<tr class="odd">
<td><strong>3. Fund Utilization &amp; SEBI Compliance</strong></td>
<td>Deviation from original fund use without prior shareholder approval triggered a <strong>clarification request from NSE</strong> (Sept‚Äô25). Even with retroactive approval, <strong>governance concerns</strong> may affect market trust.</td>
</tr>
<tr class="even">
<td><strong>4. Dependence on Tax Timing for Profitability</strong></td>
<td>A significant portion of profit in Q1 came from <strong>deferred tax credit</strong> (‚Çπ42.75 crores). Sustainable operational EBITDA remains modest.</td>
</tr>
<tr class="odd">
<td><strong>5. Scale of ‚ÄúOther Current Assets‚Äù</strong></td>
<td>‚Çπ1347 crores in ‚ÄúOther Current Assets‚Äù ‚Äî needs transparent disclosure. If these are inter-corporate investments or unsecured loans, <strong>credit risk exposures</strong> increase.</td>
</tr>
<tr class="even">
<td><strong>6. Retail Venture Success Uncertain</strong></td>
<td>Retail healthcare in India is fiercely competitive (Apollo, Medlife, PharmEasy, etc.). <strong>Proven track record required</strong> to de-risk ‚Çπ1650 crores investment.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="financial-highlights-standalone-h1-fy26-sep25" class="section level6">
<h6>üìä <strong>Financial Highlights (Standalone, H1 FY26 ‚Äî Sep‚Äô25)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY26 (‚Çπ in crores)</th>
<th>H1 FY25 (‚Çπ in crores)</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue from Operations</strong></td>
<td>4786.80</td>
<td>4534.55</td>
<td>+5.6%</td>
</tr>
<tr class="even">
<td><strong>Total Income</strong></td>
<td>4786.80</td>
<td>4534.55</td>
<td>+5.6%</td>
</tr>
<tr class="odd">
<td><strong>Total Expenses</strong></td>
<td>4725.44</td>
<td>4527.72</td>
<td>+4.4%</td>
</tr>
<tr class="even">
<td><strong>PBT (Before Tax)</strong></td>
<td>61.35</td>
<td>(157.18)</td>
<td>Turnaround</td>
</tr>
<tr class="odd">
<td><strong>Net Profit</strong></td>
<td>85.90</td>
<td>(964.23)</td>
<td>Strong improvement</td>
</tr>
<tr class="even">
<td><strong>EPS (Basic)</strong></td>
<td>‚Çπ0.10</td>
<td>(‚Çπ1.13)</td>
<td>Positive shift</td>
</tr>
<tr class="odd">
<td><strong>Cash &amp; Equivalents</strong></td>
<td>1,681.90</td>
<td>~130.57</td>
<td>+12.8x growth (capital-driven)</td>
</tr>
<tr class="even">
<td><strong>Operating Cash Flow</strong></td>
<td>(‚Çπ293.33)</td>
<td>‚Çπ67.85</td>
<td>Sharp deterioration</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="final-assessment-outlook" class="section level6">
<h6>‚úÖ <strong>Final Assessment &amp; Outlook</strong></h6>
<table>
<colgroup>
<col width="33%" />
<col width="33%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Rating</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Trajectory</strong></td>
<td>‚≠ê‚≠ê‚≠ê‚òÜ‚òÜ</td>
<td>Revenue growth is solid; future expansion plans offer upside.</td>
</tr>
<tr class="even">
<td><strong>Profitability</strong></td>
<td>‚≠ê‚≠ê‚≠ê‚≠ê‚òÜ</td>
<td>Net profitability restored but heavily boosted by deferred tax. Watch core EBITDA.</td>
</tr>
<tr class="odd">
<td><strong>Cash Flow Health</strong></td>
<td>‚≠ê‚≠ê‚òÜ‚òÜ‚òÜ</td>
<td>Weak operating cash flow is a serious concern. Risk of dependency on funding.</td>
</tr>
<tr class="even">
<td><strong>Strategic Vision</strong></td>
<td>‚≠ê‚≠ê‚≠ê‚≠ê‚òÜ</td>
<td>Fund repurposing to retail venture shows bold, forward-looking strategy.</td>
</tr>
<tr class="odd">
<td><strong>Governance</strong></td>
<td>‚≠ê‚≠ê‚≠ê‚òÜ‚òÜ</td>
<td>Deviation in fund use raised flags ‚Äî retroactive shareholder approval mitigates, but process needs improvement.</td>
</tr>
<tr class="even">
<td><strong>Overall Outlook</strong></td>
<td><strong>Neutral to Positive (Medium-Term Bullish)</strong></td>
<td>If the company stabilizes working capital and successfully executes new projects, significant upside exists. However, <strong>near-term cash flow pressure remains a red flag</strong>.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="recommendations-for-stakeholders" class="section level6">
<h6>üõ†Ô∏è Recommendations for Stakeholders</h6>
<ul>
<li><strong>Investors</strong>: Monitor <strong>cash flow trends</strong> closely. Short-term momentum looks positive, but long-term viability depends on converting revenue into cash.</li>
<li><strong>Management</strong>: Improve working capital cycle ‚Äî <strong>tighten receivables, control inventory</strong>, and provide clearer disclosures on ‚ÄúOther Current Assets‚Äù.</li>
<li><strong>Regulators (SEBI)</strong>: Ensure future fund re-allocations are pre-approved. Enhanced disclosure of fund deployment timelines.</li>
<li><strong>Analysts</strong>: Await full-year FY26 results to assess if retail venture and J&amp;K project deliver returns.</li>
</ul>
<hr />
<div id="conclusion" class="section level9">
<p class="heading">üèÅ Conclusion</p>
<p><strong>JHS Svendgaard is at an inflection point</strong> ‚Äî leveraging a large capital raise to transform from a <strong>manufacturing-focused pharma company</strong> into a <strong>vertically integrated player</strong> with retail ambitions. Strong top-line growth and restored profitability are promising, but <strong>unsustainable working capital practices and cash outflows pose a material risk</strong>. The next 12‚Äì18 months will be critical in determining whether this strategic pivot <strong>delivers value or leads to further financial strain</strong>.</p>
<blockquote>
<p><strong>Bottom Line</strong>: <strong>Cautious optimism</strong> ‚Äî momentum is building, but <strong>execution and cash conversion are key</strong>.</p>
</blockquote>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
